MAP3K5 and metabolic dysfunction-associated steatohepatitis: Previous in vivo studies have demonstrated that inhibition of ASK1 can effectively reduce liver and kidney injury and fibrosis and may be a possible therapeutic target for non-alcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD) [52].